APA Citation

Fala, L. (2015). Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits.

Citação norma Chicago

Fala, Loretta. "Invokamet (Canagliflozin Plus Metformin HCl): First Fixed-Dose Combination With an SGLT2 Inhibitor Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.

MLA Citation

Fala, Loretta. "Invokamet (Canagliflozin Plus Metformin HCl): First Fixed-Dose Combination With an SGLT2 Inhibitor Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.

Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.